Michael Cohen

Practice Areas

TRANSACTIONS

LIFE SCIENCES

EMERGING GROWTH COMPANIES & VENTURE CAPITAL

PRIVATE EQUITY TRANSACTIONS

CAPITAL MARKETS

CROSS-BORDER TRANSACTIONS

MERGERS & ACQUISITIONS

TECHNOLOGY

FINTECH

DIGITAL COMMERCE

INVESTMENT MANAGEMENT

Work Highlights

Crossbow Therapeutics, a biotechnology company developing a novel class of antibody therapies for cancers, in its $80 million Series A financing.

Aktis Oncology, a clinical stage oncology company focused on radiopharmaceuticals, in its $161 million Series A financing, its $175 million Series B financing, a strategic investment by Eli Lilly and Company, and other strategic matters as outside general counsel.

Sincere, the parent company of consumer-focused web services Punchbowl, Memento, Timehop, and Lovebird, in connection with various financings, acquisitions, and other strategic matters as outside general counsel.

Scrum Inc., a provider of business services, training, and credentialing related to the Scrum agile methodology, in multiple international joint ventures and other strategic matters as outside general counsel.

Crosslink Therapeutics, a development stage oncology company, in a SAFE financing.

Oliva Health, a facilitator of web-based mental health coaching services, in various equity financings.

Eliem Therapeutics (now Climb Bio), a clinical stage biotechnology company developing therapeutics for immune-mandated diseases, in its Series A-1 financing and expansion into the United Kingdom.

Pallidus, a manufacturer of silicon carbide-based semiconductors, in multiple equity financings and other strategic matters as outside general counsel.

Prognos Health, a healthcare AI company, in a $23 million preferred stock financing.

FieldAware Group, a portfolio company of The Oyster Group, in the acquisition of Skeds.

Nexus NeuroTech Ventures in funding the spin-out and launch of Lotus Neuro, a new clinical stage biotechnology company advancing the next generation of brain-targeted therapeutics through precision, low frequency-focused ultrasound, from portfolio company Insightec.

MPM BioImpact, a world-leading biotechnology-focused fund, in financing and corporate law matters involving portfolio companies, including in the:

$40 million Series A financing of āshibio, a California-based biotech company.

$20 million Series B-2 financing of Deka Biosciences, a Maryland-based biotech company.

RA Capital Management, a multi-stage investment manager investing in healthcare, life sciences, and planetary health companies, in financing and corporate law matters involving portfolio companies, including in the:

$72 million Series B financing of Werewolf Therapeutics.

$24 million Series B financing of Selux Diagnostics.

$64 million financing of Synthorx.

$150 million Series E financing of Peloton Therapeutics.

$60 million financing of 89Bio Ltd.

Series B Preferred Share financing of WhiteSwell, and a share exchange resulting in the redomiciling of WhiteSwell from Israel to Ireland.

$50 million Series C crossover financing of Solid Biosciences.

Material Impact, an investment firm dedicated to advancing novel material science, in financing and transactional matters involving several portfolio companies.

the $10 million Series B financing for agriculture-tech company AgZen.

the $11.4 million Series A financing of Tierra Biosciences, an AI-aided operator of a synthetic biology company intended to accelerate the pace of discovery to enable the next generation of bioengineered products.

the preferred stock financing of Werewool, developer of a biomaterials development platform.

The University of Oxford, Oxford University Innovation, and Oxford Science Enterprises in various U.S. spin-out and portfolio company matters.

Highland Europe and True Ventures as lead counsel in the $120 million Series B financing of Zwift.

OMERS Private Equity in the acquisition of Golfsmith International Holdings by portfolio company Golf Town.

Career

Michael Cohen is co-practice group leader of Brown Rudnick’s Global Life Sciences Group and of the firm’s Emerging Growth Companies & Venture Capital Group. He advises on high-profile matters in the life sciences and technology sectors. Michael's clients regularly rely on him to be a true outside general counsel, ready and able to handle matters big and small as they arise.

Michael represents early stage and mid-market companies in corporate structuring, mergers and acquisitions, joint ventures and strategic alliances, financing transactions, and other general transactional matters at all stages of the corporate life cycle. Michael also advises venture, hedge, and private equity funds, universities, corporate venture groups, and portfolio companies in connection with financing transaction deal terms and stockholders' agreements, technology licensing, corporate governance and securities law compliance in connection with private offerings.

Michael also works closely with Brown Rudnick’s London office in counseling U.K. and European clients engaging in transactions involving U.S. concerns.

Education